Project News

A CRITICAL KISS: FROM MACRO TO MICRO

While the fabrication of a self-assembled network of capillaries and an engineered macro-network is not trivial but possible, the connection between the two is a real challenge. “The macro-to-micro connection proposed by B2B is truly innovative and, to the best of our knowledge, it’s the first time that it would be implemented” explains Andrea Banfi, leader of the related work…

TO EACH TISSUE, ITS MICRO-NETWORK

In B2B, both the breast tumoroid and the ossicle have their self-assembled networks of capillaries. In the first case, the tumoroid and its vascular network are generated in parallel. “We include cancer cells together with endothelial cells in a matrix of fibrin that contains growth factors for both tissues.” explains Andrea Banfi. Thanks to the biological signals, the system evolves…

MACRO & MICRO in B2B

As stated in the name of the project (from Breast to Bone), B2B relies on the connection between two tissues. Indeed, the two chambers, one with the breast tumoroid and the other with the ossicle, are connected with a system that resembles the physiological blood circulation, a set of vessels that brings the blood with oxygen and nutrients to the…

Therapeutic Angiogenesis

The B2B partner Andrea Banfi directs the Cell and Gene Therapy group at Basel University Hospital, in the Departments of Biomedicine and of Surgery. His research focus is the understanding of the basic principles governing the growth of blood vessels and translating this knowledge into the development of novel therapies. We asked him to introduce us to the concept of…

THE PROJECT SYNERGY: THE CONSORTIUM

The B2B Consortium collects the excellence of several sectors, each one contributing to a specific component of the device. Only the synergy between all the parts gives life to the B2B device. The realization of the breast cancer model from a patient-derived primary lesion is led by Nicola Aceto at the Cancer Metastasis lab of the University of Basel, winner…

STUDY CANCER METASTASIS IN CLINICALLY RELEVANT MODELS

Unable to validate some of their hypothesis, scientists often remain with many pending questions about cancer, especially regarding the metastatic process and the failure of preclinical studies: how come that some cancer cells exit the site of origin, enter the blood flow and attack another tissue? Why certain drugs do not have the expected effect in patients compared to pre-clinical…

RESEARCH TO INNOVATE CANCER RESEARCH

Research, in order to advance and fuel innovation, needs technological innovation itself. The EU-funded project B2B is doing research for researchers, to bring recent advances in fluidic systems and 3D printing to the biomedical sector. “When a new technology reaches the biomedical field, all eyes are on the technology and its advantages – but to have a successful uptake, the…

AN INTRINSICALLY FET PROJECT

B2B it’s a Future & Emerging Technologies (FET) project. This EU-funded Programme is all about transforming advanced scientific ideas into radically new technologies for the future. As for the B2B platform, the breakthrough technology should not be incremental but truly revolutionary, changing the today paradigms. We asked our project coordinator Silvia Scaglione to describe the innovation behind B2B and why…

B2B project has started

B2B project has officially started on July 1, 2018. During the next 4 years, the Consortium will be busy developing a novel hybrid device able to model the spontaneous breast cancer metastasis to the bone. The project has been funded for a total of 3.8M€ under the FET OPEN call of the European Union’s Horizon 2020 Framework Programme. The full official information…